Chateal Eq

Quick links to important sections

Chateal Eq

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chateal Eq

Quick Facts

Property Description
Active ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Contraceptive Tablet
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Contraception
Origin Synthetic Hormones

What Type of Medicine is Chateal Eq?

Chateal Eq is a specific prescription-only medication classified as a Combined Hormonal Contraceptive (CHC), an Estrogen-Progestin Combination administered via the oral route. The active ingredients belong to the drug class of Contraceptives.

This medicine is a type of monophasic oral contraceptive, meaning the amount of Ethinyl Estradiol and Levonorgestrel remains fixed across all active tablets in the cycle. This fixed-dose regimen is recognized for providing consistent hormonal support, which is vital for sustained hormonal regulation in women of reproductive age.

What Active Ingredients are in Chateal Eq and How Do They Work?

The active ingredients in this combination product are the synthetic hormones Ethinyl Estradiol and Levonorgestrel. The Ethinyl Estradiol component acts as the Synthetic Estrogen, while Levonorgestrel provides the Synthetic Progestin activity. This specific formulation is one of several versions of this generic combination.

This combination is utilized for its efficacy in preventing pregnancy. The drug’s primary purpose is to provide reliable contraception through synchronized hormonal action, mainly via ovulation inhibition and the alteration of cervical mucus.

How Does This Combination Differ from Other Oral Forms?

As a Combination Product, this medicine utilizes a dual-hormone strategy, setting it apart from progestin-only pills (POPs) and providing multiple points of intervention in the reproductive cycle. Furthermore, its monophasic structure ensures a constant, stable hormonal exposure during the active period. This consistent dose profile of the oral contraceptive tablet simplifies the classification and administration type compared to formats that vary hormone doses across the cycle.

Regulatory References

  1. NIH DailyMed: Ethinyl Estradiol and Levonorgestrel Tablets

What side effects are possible with Chateal Eq?

Possible side effects and safety information

The official safety profile for Chateal Eq, a combined hormonal contraceptive, is structured around frequency classifications and specific serious risks documented by regulatory authorities (e.g., FDA, EMA).

Commonly Documented Adverse Reactions

Adverse reactions classified as common in official labeling (occurring in 1% to 10% of users) generally involve several physiological systems. These effects include headache, nausea, abdominal pain, and breast tenderness. Other commonly reported effects are weight increase, mood changes, and bleeding irregularities such as breakthrough bleeding or spotting, particularly noted during the first few cycles of use.

System Organ Class Common Adverse Reactions (Examples)
Reproductive System Breast pain, Irregular uterine bleeding
Nervous System Headache, Migraine
Gastrointestinal Nausea, Vomiting, Abdominal pain

Serious Adverse Reactions and Constraints

The most serious, though rare, safety risk documented for combined hormonal contraceptives is the development of venous and arterial thromboembolic events, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. This risk defines critical contraindications in the official labeling.

The medicine is formally contraindicated in individuals with a high risk of thrombotic disease. Specific constraints prohibit use in females over age 35 who smoke, individuals with uncontrolled hypertension, certain liver diseases (e.g., severe cirrhosis or liver tumors), and those with a history of migraines with aura.

Other documented safety considerations include the possibility of developing or worsening hypertension and the need to monitor blood pressure. The drug should also be discontinued before and after major surgery or during periods of prolonged immobilization due to the elevated risk of thromboembolism.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on official regulatory prescribing information for combined hormonal contraceptives. An acute overdose of Chateal Eq (Ethinyl Estradiol and Levonorgestrel) is generally not likely to be life-threatening.

Documented Overdose Manifestations

Official regulatory documents state that the most common signs following ingestion of several dosage units at once may include nausea and vomiting.

Another expected manifestation is withdrawal bleeding, which may occur several days after the overdose event and can be heavy. Additional reported symptoms include drowsiness, fatigue, and breast tenderness.

Required Emergency Actions

The most critical aspect of the drug's safety profile is the risk of Thromboembolic Disorders (blood clots, stroke, heart attack). Although not direct signs of overdose, the symptoms of these life-threatening events require immediate and mandatory action, as stated in regulatory warnings.

Urgent medical help must be sought immediately if symptoms such as sudden severe headache, sudden vision changes, slurred speech, chest pain, or unexplained pain/swelling in the leg are experienced. In these situations, individuals must contact emergency services right away.

Management for an overdose is defined by regulators as symptomatic and supportive treatment, as no specific antidote is officially documented for this combination of hormones.

Therapeutic Uses of Chateal Eq

What Chateal Eq Treats: Main Uses and Benefits

Contraception and Symptom Management

The combination of hormones in this oral contraceptive is primarily indicated for effective pregnancy prevention, offering effective, long-term contraception for females of reproductive potential. This medication is also commonly used to address a range of gynecological conditions, providing supportive non-contraceptive therapeutic benefit.

Chateal Eq is relevant for managing symptom clusters that may become intense or disruptive, such as menstrual cycle dysregulation. This combined therapy is relevant for easing the intensity of painful periods (dysmenorrhea) and is applied in addressing the volume of heavy periods (menorrhagia). The medication is also commonly used to help with hormonal manifestations, such as persistent acne vulgaris and the intense mood changes of Premenstrual Dysphoric Disorder (PMDD). This benefit provides support that helps ease the overall symptom burden.

Long-term use may also be associated with important prophylactic advantages, including a reduced risk of developing certain severe conditions like endometrial cancer and ovarian cancer, and may assist with managing the frequency of functional ovarian cysts.

Quick Fact: Symptomatic Relief Domains This therapy is commonly used to help manage menstrual pain and heavy bleeding, supports skin clarity by addressing hormonal acne, and is relevant for easing the mood symptoms of PMDD.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Chateal Eq?

Eligibility for Chateal Eq is strictly defined by regulatory documents, which establish clear restrictions to minimize risks, primarily thromboembolism and effects on hormone-sensitive conditions.

Who Cannot Use Chateal Eq (Contraindications)

Chateal Eq is formally contraindicated and must not be used by individuals with the following high-risk conditions, as documented by the FDA:

  • Age and Smoking: Females over age 35 who smoke.
  • Vascular Disease: A current or history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cerebrovascular Disease (e.g., stroke), or Coronary Artery Disease.
  • Coagulation/Metabolic: Known hypercoagulopathies, uncontrolled hypertension, or diabetes with vascular disease.
  • Migraine: Migraine headaches with aura.
  • Hormone-Sensitive History: Current or history of breast cancer or liver tumors.
  • Pregnancy: The medication is contraindicated in pregnancy and must be discontinued if pregnancy occurs.

Conditional and Restricted Use

  • Postpartum: Use is not recommended earlier than four weeks after delivery due to increased thromboembolism risk.
  • Lactation: The drug is not recommended for nursing mothers as it may decrease milk production.
  • Age Groups: Use is not indicated before the onset of menstruation (pre-menarche) or in postmenopausal women.

What should I know about interactions with other medicines?

Chateal Eq (levonorgestrel and ethinyl estradiol tablets) can interact with various medicinal products and substances, affecting either the effectiveness of the contraceptive or the concentration of the co-administered drug.

Contraindicated Combinations

Concomitant use of Chateal Eq with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is contraindicated. This is due to the potential for significant increases in the liver enzyme alanine aminotransferase (ALT) levels.

Interactions Affecting Chateal Eq

Certain medicines can decrease the plasma concentrations of the ethinyl estradiol and levonorgestrel components, which may reduce contraceptive efficacy and increase the risk of breakthrough bleeding. These include drugs that are potent inducers of hepatic enzymes, such as rifampin, barbiturates, and certain anticonvulsants (e.g., phenytoin, topiramate). The herbal product St. John's Wort can also induce enzymes, potentially affecting hormone levels. Decreased exposure to the estrogen component can also occur with products that bind to the hormones, such as colesevelam.

Conversely, substances that inhibit certain liver enzymes, such as CYP3A4 inhibitors (e.g., indinavir, fluconazole), may increase the hormone concentrations, although a specific risk of intrahepatic cholestasis is noted with troleandomycin.

Interactions Affecting Other Medicines

Oral contraceptives can inhibit the clearance of other drugs, leading to increased plasma concentrations of those medicines. Examples include the immunosuppressant cyclosporine and the bronchodilator theophylline. Chateal Eq may also significantly decrease the systemic exposure of lamotrigine, a medicine used for seizures, potentially reducing its effectiveness.

Mechanism of Action

Central Endocrine Axis Modulation

The combination of ethinyl estradiol and levonorgestrel modulates the hypothalamic-pituitary-ovarian axis. This hormonal modulation results in the suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. The suppression of LH and FSH secretion results in the absence of a mid-cycle LH surge, which inhibits dominant follicle selection and maturation. Ethinyl estradiol also acts on estrogen receptors (ER) in various tissues, including bone.


Peripheral Tissue Effects

Additionally, the progestin component (levonorgestrel) modifies cervical mucus properties. This modification increases cervical mucus viscosity and decreases sperm motility. Finally, the progestin-mediated effect alters the endometrial morphology.

Dosage and Administration Information

How Chateal Eq is Used: Dosing and Administration

Chateal Eq is administered via the oral route as a tablet and is packaged in a 28-day cycle dispenser. This medicine is used according to a precise, continuous cyclic schedule, requiring the user to take one tablet daily for 28 consecutive days.


Standard Regimen

The standard adult dosing regimen requires taking one tablet daily at the same time each day, which may be done with or without food.

Cycle Phase Duration Tablet Type Active Dosing
Hormone Phase 21 Days (Days 1–21) Active Tablet Fixed daily dose of 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol
Placebo Phase 7 Days (Days 22–28) Inactive Tablet No hormones

Use Initiation and Continuation

Two starting options exist for the first pack: the Day 1 Start (first day of the menstrual period) or the Sunday Start (first Sunday after the period begins). If using the Sunday Start, a back-up non-hormonal contraceptive method must be used for the first seven days of tablet taking. A new 28-day pack must be started the day after the last tablet in the previous pack is finished, without interruption.

Usage is generally reserved for females of reproductive potential. Postpartum initiation in non-breastfeeding females is recommended no earlier than four weeks after delivery.

Recent Clinical Evidence

Research evidence / Overview of studies for Chateal Eq

Evidence for Contraception and Cycle Management

The foundation of knowledge for combined oral contraceptives like Chateal Eq is based on extensive research, including a high volume of Randomized Controlled Trials (RCTs) and Large Prospective Cohort Studies. These studies were primarily conducted to evaluate the efficacy of this class of medicine in pregnancy prevention. Researchers monitored large populations of healthy women of reproductive age over defined time intervals to gather data on the rate of unintended pregnancy. The findings describe group patterns related to monitored pregnancy rates under specific study conditions, which regulatory bodies use as the basis for this primary indication.

Beyond pregnancy prevention, research has explored the application of this combined therapy in studies related to common conditions characterized by fluctuating or episodic manifestations, such as heavy menstrual bleeding (menorrhagia) and painful periods (dysmenorrhea). Studies for this outcome, often RCTs, were conducted during periods of increased symptom activity and focused on outcomes related to systemic or functional imbalance. Specifically, studies monitored and examined the volume of menstrual blood loss over a series of treatment cycles. For painful periods (dysmenorrhea), trials explored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort.


Evidence for Skin and Mood-Related Conditions

This part of the evidence base focuses on trials that examined the application of the medicine beyond its primary contraceptive purpose, specifically for acne vulgaris and Premenstrual Dysphoric Disorder (PMDD).

Research on Hormonal Acne Outcomes

The research exploring outcomes related to inflammatory or irritative states of the skin is based on controlled research, typically double-blind, placebo-controlled trials. These studies focused on females presenting with mild to moderate facial acne. Researchers monitored objective dermatological outcomes, including the number of lesions and specific scores assigned by clinicians assessing overall skin condition. Studies report how symptoms evolved in the observed populations over six active cycles.

Research on PMDD Symptom Evaluation

Studies exploring PMDD examined temporary physiological imbalance related to severe premenstrual mood changes. This was evaluated in Randomized Controlled Trials using standardized rating scales, such as the Daily Record of Severity of Problems (DRSP), to monitor emotional and physical symptoms. The evidence base here is categorized as having a Moderate evidence level. However, regulatory reviews have noted that findings were mixed across different trials, and a large proportion of reported change was also observed in the placebo groups.

Frequently Asked Questions (FAQ)

Common questions about Chateal Eq (FAQ)


Q: What is the main difference between Chateal Eq and other similar medicines?

Chateal Eq is classified as a monophasic Combined Oral Contraceptive (COC), meaning it uses a fixed dose of two synthetic hormones (ethinyl estradiol and levonorgestrel) throughout the active portion of the cycle. While all COCs work via hormonal regulation, different brands contain various types and amounts of hormones. These variations in formulation can sometimes lead to differences in the side effect profile experienced by individual users.


Q: How quickly can someone expect to see results from Chateal Eq?

According to the official product information, protection against pregnancy may begin after seven consecutive days of taking the active pills. If a user starts the pack on the first day of their menstrual period, back-up contraception is typically not required. However, if using the alternative Sunday Start method, official labeling describes the use of a back-up method as necessary for the first seven days.


Q: Are there any long-term effects associated with using Chateal Eq?

Long-term use of this class of medicine is associated with a well-documented risk of venous and arterial thromboembolic events (blood clots) compared to non-users. While contraceptive effectiveness is maintained, official documents highlight that individual risk factors require ongoing evaluation while using this medication. The risk of these serious events generally decreases after the medication is discontinued.


Q: Is Chateal Eq known to interact with caffeine?

Official information describes that the estrogen component of this medication, ethinyl estradiol, may increase the blood levels of caffeine in the body. This potential change in concentration may elevate the risk or severity of common side effects associated with caffeine consumption. Individuals who regularly consume caffeine may note this potential interaction.


Q: Can Chateal Eq be taken if I am also using certain vitamins or supplements?

Interactions are known to occur between combined hormonal contraceptives and certain supplements, such as the herbal product St. John's Wort, which can reduce the effectiveness of the contraceptive. For this reason, official patient information typically outlines the importance of disclosing all prescription medications, nonprescription medicines, and any supplements to a healthcare provider.


Q: Is Chateal Eq considered safe for younger adult populations?

The medication is indicated for use in females of reproductive potential. Its safety profile is generally established for this population, but official labeling notes that use is not indicated before the onset of menstruation (pre-menarche). An individual risk assessment for thromboembolism (blood clots) is applicable to users of all ages.


Q: Is Chateal Eq the same as its generic version?

Chateal Eq is a brand-name product containing a combination of the active ingredients levonorgestrel and ethinyl estradiol. Regulatory agencies approve generic versions that contain the exact same active ingredients in the same strength. These generic versions are considered by the FDA to be therapeutically equivalent to the brand-name product.


Q: Are there any specific foods that are described as interacting with Chateal Eq?

The official product information states that the medicine can be taken with or without food. Some authoritative sources note that specific food products, such as grapefruit or grapefruit juice, may potentially interact with the hormones. Individuals who regularly consume these products may note the potential for adverse effects.


Q: Does Chateal Eq have a Black Box Warning, and what does it indicate?

Combined oral contraceptives, including Chateal Eq, carry significant cautionary notes in a Boxed Warning format in official documentation. This warning highlights the serious cardiovascular risks associated with this class of medicine. This risk is notably elevated for women over age 35 who smoke, which is a key contraindication.


Q: How long does the effect of a Chateal Eq dose typically last?

The hormones in this medication have specific half-lives, which is the rate at which the drug concentration is processed by the body. Due to this processing rate, the medication relies on consistent daily dosing to maintain the necessary hormonal levels for contraceptive efficacy. This is why the patient labeling describes the importance of consistent daily tablet administration, without exceeding a 24-hour interval between doses.


Q: Are there specific symptoms that require contacting a healthcare professional when using Chateal Eq?

Official warnings describe symptoms associated with serious, though rare, adverse reactions like blood clots. These symptoms may include sudden severe headache, slurred speech, chest pain, difficulty breathing, or pain and swelling in the legs. Regulatory documents describe seeking immediate attention as appropriate if these signs of a stroke, heart attack, or blood clot (DVT/PE) are observed.


Q: Can Chateal Eq affect my ability to drive or operate machinery?

The official product information for the medicine does not typically list impairment of the ability to drive or use machinery. However, commonly reported adverse reactions like headaches or nausea could potentially affect a user's attention or physical well-being. Individuals may note their personal reaction to the medication before performing tasks that require concentration.


Q: Why is Chateal Eq sometimes associated with changes in vision?

Combined oral contraceptives have been associated with rare ocular effects in some reports. These issues include the potential for retinal vein thrombosis (blood clot in the eye) or optic neuritis. Official warnings describe that if blurred vision, difficulty reading, or any other change in vision occurs, regulatory information advises that medical evaluation is appropriate.


Q: Does Chateal Eq cause dependency or withdrawal issues?

Official information indicates that this class of medicine does not cause physical or psychological dependency. However, some symptoms such as headaches, bloating, and breast tenderness are known to occur during the seven-day hormone-free interval (when the placebo pills are taken). These temporary symptoms are often referred to as withdrawal bleeding.


Q: What are the signs of a serious, though rare, allergic reaction to Chateal Eq?

The official patient labeling describes signs of a serious allergic reaction. These may include rash, hives, or swelling of the face, lips, tongue, or throat. Symptoms such as trouble breathing, difficulty swallowing, or wheezing are also described as requiring prompt attention in the official labeling.


Q: Is Chateal Eq considered safe for long-term use?

Contraceptive effectiveness is maintained with long-term use. However, the associated risk of serious adverse events, particularly cardiovascular risks, remains throughout the period of use. The official documentation describes that continuous assessment of individual risk factors by a healthcare provider is important, especially in light of changing risk factors like age or smoking status.


Q: Are there any known drug interactions for Chateal Eq that involve antibiotics?

Interactions are known with some specific antibiotics, such as Rifampin, which can significantly reduce the effectiveness of the contraceptive. While some other antibiotics may also carry an associated risk of reduced efficacy, that risk is generally considered low. Individuals may review official drug labeling for guidance on whether backup contraception is noted as necessary when starting a new medication.


Q: What is the general success rate mentioned in the research for Chateal Eq?

Clinical trials for combined oral contraceptives demonstrate high efficacy for preventing pregnancy. According to estimates based on regulatory data, the failure rate with perfect use is approximately 0.3 pregnancies per 100 women per year. The failure rate is estimated to be around 8 pregnancies per 100 women per year with typical use.


Q: What steps are officially recommended if a user accidentally takes too much Chateal Eq?

Official product information suggests that serious adverse effects from acute overdose are generally not expected. Symptoms that may occur include nausea, vomiting, and potential withdrawal bleeding. In the event of an overdose, patient labeling describes contacting a healthcare professional or poison control center as the appropriate action.


Q: Are the side effects of Chateal Eq dose-dependent?

Chateal Eq is classified as a monophasic product, meaning it provides a consistent, fixed daily amount of both the estrogen and progestin hormones in the active pills. While the likelihood and severity of side effects in combination contraceptives can sometimes relate to the dose of the hormones, this product delivers a stable hormonal profile during the active phase of the cycle.


Q: Can Chateal Eq be taken with over-the-counter pain relievers?

Interactions between the components of the oral contraceptive and common over-the-counter pain relievers, such as acetaminophen or ibuprofen, are generally not classified as major. However, hormonal contraceptives can inhibit the clearance of certain drugs, which may potentially lead to increased concentrations of those drugs. Official information describes that disclosure of all medicines, including OTC pain relievers, to a healthcare provider is recommended.


Q: Is it possible for Chateal Eq to affect laboratory test results?

Yes, official documentation indicates that the use of combined oral contraceptives can affect the results of certain laboratory tests. This interference may be noted in tests related to liver function, thyroid binding globulin, coagulation factors, and blood lipids. Healthcare professionals are advised to be aware of this potential when interpreting lab results.


Q: What is the appearance of the Chateal Eq pill?

The active tablets, taken during the first 21 days of the cycle, are described in the official product labeling as being orange, round, and typically imprinted with brand-specific identifiers. The seven inactive (placebo) tablets, which contain no hormones, are green.


Q: Are there different strengths available for Chateal Eq?

The specific brand-name product, Chateal Eq, is available only in its fixed dose combination of levonorgestrel and ethinyl estradiol. However, the generic components themselves (levonorgestrel and ethinyl estradiol) are widely available under various other brand names and in different fixed-dose strengths.

How should Chateal Eq be stored and disposed of?

How to Store and Dispose of Chateal Eq?

This section outlines the official, regulatory requirements for storing and disposing of Chateal Eq (Levonorgestrel and Ethinyl Estradiol Tablets).

Official Storage Requirements

Requirement Details
Temperature Store at controlled room temperature, between 68° to 77°F (20° to 25°C). Avoid exposing the medication to freezing or excessive heat.
Protection The product must be protected from light and kept in its original blister packaging.
Safety Keep the medication out of the sight and reach of children and pets.

Disposal Instructions

Official instructions mandate that any unused or expired Chateal Eq tablets must be thrown away after the expiration date on the package. Always check for specific local pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Chateal Eq found in:

A-Z Index: